- Home
- CPSS vs PLX Comparison
CPSS vs PLX Comparison
Compare CPSS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPSS
- PLX
- Stock Information
- Founded
- CPSS 1991
- PLX 1993
- Country
- CPSS United States
- PLX United States
- Employees
- CPSS N/A
- PLX N/A
- Industry
- CPSS Finance: Consumer Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPSS Finance
- PLX Health Care
- Exchange
- CPSS Nasdaq
- PLX Nasdaq
- Market Cap
- CPSS N/A
- PLX 160.2M
- IPO Year
- CPSS 1992
- PLX 1998
- Fundamental
- Price
- CPSS $9.88
- PLX $2.87
- Analyst Decision
- CPSS
- PLX Strong Buy
- Analyst Count
- CPSS 0
- PLX 1
- Target Price
- CPSS N/A
- PLX $15.00
- AVG Volume (30 Days)
- CPSS 13.3K
- PLX 753.1K
- Earning Date
- CPSS 05-16-2025
- PLX 05-09-2025
- Dividend Yield
- CPSS N/A
- PLX N/A
- EPS Growth
- CPSS N/A
- PLX N/A
- EPS
- CPSS 0.79
- PLX 0.04
- Revenue
- CPSS $185,463,000.00
- PLX $53,399,000.00
- Revenue This Year
- CPSS $161.83
- PLX $65.02
- Revenue Next Year
- CPSS $15.69
- PLX $57.34
- P/E Ratio
- CPSS $12.51
- PLX $79.67
- Revenue Growth
- CPSS N/A
- PLX N/A
- 52 Week Low
- CPSS $7.03
- PLX $0.82
- 52 Week High
- CPSS $12.73
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CPSS 61.07
- PLX 56.85
- Support Level
- CPSS $8.76
- PLX $2.70
- Resistance Level
- CPSS $9.20
- PLX $2.64
- Average True Range (ATR)
- CPSS 0.40
- PLX 0.17
- MACD
- CPSS 0.13
- PLX -0.01
- Stochastic Oscillator
- CPSS 93.57
- PLX 61.67
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.